Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387340 | 1.00 | CNR2 (0.54) | CNR2CNR1KMT2AALDH1A1RAB9A | |
| SCHEMBL3446794 | 0.81 | CNR2 (0.62) | CNR2CNR1KMT2AALDH1A1RAB9A | |
| SCHEMBL5128396 | 0.81 | CNR2 (0.62) | CNR2CNR1KMT2AALDH1A1RAB9A | |
| SCHEMBL3384496 | 0.81 | CNR2 (0.65) | CNR2CNR1KMT2AALDH1A1RAB9A | |
| SCHEMBL3384491 | 0.81 | CNR2 (0.65) | CNR2CNR1KMT2AALDH1A1RAB9A | |
| SCHEMBL5121899 | 0.79 | CNR2 (0.57) | CNR2CNR1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5121890 | 0.79 | CNR2 (0.57) | CNR2CNR1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3382654 | 0.79 | CNR2 (0.62) | CNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL3382648 | 0.79 | CNR2 (0.62) | CNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL3383099 | 0.77 | CNR2 (0.57) | CNR2CNR1KMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885KMT2A 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.